Holen Sie sich die Stockscreener-App
26.72
5.49%
1.39
Handel nachbörslich:
26.72
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Zymeworks Inc outlines its biotech strategy as investors track clinical progress - AD HOC NEWS
Form 4 Zymeworks Inc For: 6 July By Investing.com - Investing.com Canada
Zymeworks (ZYME) COO acquires 939 ESPP shares at discounted $22.22 - Stock Titan
Price to book forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI
Zymeworks Q1 2026 presentation: zanidatamab nears FDA decision - Investing.com
Zymeworks Inc outlines its antibody-drug conjugate strategy as investors watch oncology partnerships - AD HOC NEWS
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run - Yahoo Finance
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP
Enterprise value to revenue forward of Zymeworks Inc. – BOATS:ZYME - TradingView
The Zymeworks ZW25 bispecific antibodya flexible HER2 therapy option for oncology partners - AD HOC NEWS
Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? - Insider Monkey
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals
Zymeworks Inc. (ZYME) M&A CallSlideshow (NASDAQ:ZYME) 2026-06-30 - Seeking Alpha
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo
Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology
Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet
Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus
Zymeworks Inc. Stock 12‑Month Price Target Raised to $38.75, Implies 60% Upside - TradingView
Zymeworks offers US$929-million for COPD drug maker Theravance - The Globe and Mail
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal - Investing.com UK
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal By Investing.com - Investing.com South Africa
Zymeworks Buys Theravance To Execute On New Business Strategy - insights.citeline.com
Theravance, after clinical setbacks, agrees to $929M buyout - BioPharma Dive
Zymeworks bolsters royalty stream with Theravance buy - BioWorld News
B. Riley reiterates buy on Zymeworks stock after Theravance acquisition - Investing.com
Zymeworks to Acquire Theravance Biopharma, Inc. - wahanariau.com
B. Riley reiterates buy on Zymeworks stock after Theravance acquisition By Investing.com - Investing.com India
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma - Pharmaceutical Executive
Zymeworks to Acquire Theravance for $929 Million, But Discounted Price Triggers Shareholder Investigation - finance.biggo.com
Stifel reiterates Zymeworks stock Buy rating at $47 target By Investing.com - Investing.com South Africa
Zymeworks expands beyond cancer with $929 million Theravance acquisition - Reuters
Zymeworks Targets Long-Term Cash Generation Through Theravance AcquisitionTheravance Biopharma (NASDAQ - Benzinga
Theravance Biopharma to Be Acquired by Zymeworks for $929 Million Plus Contingent Value Rights - Minichart
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders - TradingView
Stifel reiterates Zymeworks stock Buy rating at $47 target - Investing.com
Zymeworks (ZYME) to Acquire Theravance Biopharma (TBPH) for $929M in All-Cash Transaction - Blockonomi
Zymeworks to Acquire Theravance in Strategic Merger - TipRanks
Zymeworks to Buy Theravance for $17 Per Share Plus CVR - TradingView
Zymeworks (NASDAQ: ZYME) buys Theravance, adds YUPELRI cash flows with $350M OMERS note - Stock Titan
Zymeworks to acquire Theravance Biopharma for $929 million - Investing.com
Zymeworks to acquire Theravance Biopharma for $929 million By Investing.com - Investing.com Nigeria
Zymeworks to acquire Theravance Biopharma (NASDAQ: TBPH) in $929M cash and CVR deal - Stock Titan
Zymeworks Strikes $929 Million Deal for Theravance - Bloomberg.com
Zymeworks Inc.(NasdaqGS: ZYME) dropped from Russell 3000E Index - marketscreener.com
Zymeworks Inc.(NasdaqGS: ZYME) dropped from Russell Microcap Index - marketscreener.com
Zymeworks Inc.(NasdaqGS: ZYME) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Zymeworks Inc.(NasdaqGS:ZYME) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Zymeworks Inc. Actuals & Estimates (NASDAQ:ZYME) - TradingView
ZYME Forecast — Price Target — Prediction for 2027 - TradingView
Zymeworks Inc. Actuals & Estimates (BOATS:ZYME) - TradingView
ZYME Stock Price, Quote & Chart - ChartMill
ZW191’s Broad Phase 1 Activity in Ovarian Cancer Could Be A Game Changer For Zymeworks (ZYME) - Sahm
H.C. Wainwright reiterates Zymeworks stock rating on ADC data - Investing.com UK
Zymeworks Inc (ZYME) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zymeworks (ZYME) Stock Could Be 42.3% Undervalued After Cryo EM Breakthrough - Sahm
Why Zymeworks’ zanidatamab is drawing fresh attention from cancer specialists - AD HOC NEWS
Zymeworks stock rises on Gandeeva cryo-EM partnership - Investing.com
Gandeeva and Zymeworks partner on antibody drug discovery By Investing.com - Investing.com India
Gandeeva and Zymeworks partner on antibody drug discovery - Investing.com UK
Zymeworks stock rises on Gandeeva cryo-EM partnership By Investing.com - Investing.com Australia
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):